FDA approves Coya Therapeutics’ trial of COYA 302 for ALS

As part of its partnership with Dr. Reddy’s Laboratories (DRL), FDA acceptance also triggers a $4.2 million milestone payment to Coya

Bristol Myers Squibb to present new cardiovascular data at ESC Congress 2025

Merck presents new data on cardiovascular disease at ESC Congress 2025

Merck will share two oral presentations on ASCVD treatment patterns and patient burden

Giant antibody in humans acts like a brace against bacterial toxins

Protein L is known as a “superantigen” because it can bind antibodies in unusual ways

GSK forays into oncology in India with Jemperli and Zejula

The company is bringing precision therapies for gynaecological cancers

AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib

The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study

FDA lifts hold on Rocket Pharma's gene therapy trial

Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort

Dr. Lal PathLabs pioneers AI integration in cancer diagnosis in India

The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases

BioAge Labs doses first patient in BGE-102 phase 1 trial

The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants

FDA approves first immunotherapy for recurrent respiratory papillomatosis